U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C33H53O5.Ca
Molecular Weight 1099.62
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of .ALPHA.-TOCOPHEROL CALCIUM SUCCINATE, D-

SMILES

[Ca++].CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(C)C(OC(=O)CCC([O-])=O)=C(C)C(C)=C2O1.CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]3(C)CCC4=C(C)C(OC(=O)CCC([O-])=O)=C(C)C(C)=C4O3

InChI

InChIKey=QEKBRBCVWVLFHH-QAKUKHITSA-L
InChI=1S/2C33H54O5.Ca/c2*1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-20-33(8)21-19-28-27(7)31(25(5)26(6)32(28)38-33)37-30(36)18-17-29(34)35;/h2*22-24H,9-21H2,1-8H3,(H,34,35);/q;;+2/p-2/t2*23-,24-,33-;/m11./s1

HIDE SMILES / InChI

Molecular Formula C33H53O5
Molecular Weight 529.7709
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula Ca
Molecular Weight 40.078
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000920/WC500047919.pdf http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/11/WC500014528.pdf https://www.medicines.org.uk/emc/medicine/24235 https://www.ncbi.nlm.nih.gov/pubmed/12537931

Tocophersolan (Vedrop, tocofersolan) or d-alpha-Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS) is a watersoluble derivative of the natural active (d-alpha) isomer of vitamin E. The active constituent of the medicinal product is essentially vitamin E (alpha tocopherol). Chronic congenital or hereditary cholestasis is a clinical condition where vitamin E deficiency results from an impaired bile secretion. Decreased intestinal absorption observed in chronic congenital or hereditary cholestatic patients is due to decreased bile secretion and the resulting decrease in intestinal cellular absorption. As a result, fatsoluble vitamins (i.e. vit. E) are not absorbed properly and deficiency can occur. Tocophersolan (Vedrop) is used to treat or prevent vitamin E deficiency (low vitamin E levels). It is used in children up to the age of 18 years who have congenital or hereditary chronic cholestasis and who cannot absorb vitamin E from the gut. Tocophersolan (Tocofersolan) can be absorbed from the gut in children who have difficulty absorbing fats and vitamin E from the diet. This can increase vitamin E levels in the blood and help to prevent neurological deterioration (problems in the nervous system) due to vitamin E deficiency. No treatment-related findings were reported, as all clinical observations and findings at autopsy were similar in treatment and control groups. In many of the studies, the LD50 was not determined as tocofersolan was well tolerated.

CNS Activity

Curator's Comment: Neurological symptoms were either improved or stabilized in 96% of patients with chronic congenital or hereditary cholestasis (pages 19-20)

Originator

Curator's Comment: Tocophersolan or d-a-tocopheryl polyethylene glycol succinate (TPGS, CAS Registry Number 9002-96-4) was invented by Eastman Kodak in 1950.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Vedrop

Approved Use

Tocophersolan (Vedrop) is used to treat or prevent vitamin E deficiency (low vitamin E levels). The recommended total daily dose in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis is 0.34 ml/kg/day (17 mg/kg of d-alpha-tocopherol in the form of tocofersolan). The dose should be prescribed in ml.
Palliative
Vedrop

Approved Use

Tocophersolan (Vedrop) is used to treat or prevent vitamin E deficiency (low vitamin E levels). The recommended total daily dose in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis is 0.34 ml/kg/day (17 mg/kg of d-alpha-tocopherol in the form of tocofersolan). The dose should be prescribed in ml.
Palliative
Vedrop

Approved Use

Unknown
Palliative
Vedrop

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
25 unit 1 times / day multiple, oral
Studied dose
Dose: 25 unit, 1 times / day
Route: oral
Route: multiple
Dose: 25 unit, 1 times / day
Sources:
unhealthy, CHILD
Health Status: unhealthy
Age Group: CHILD
Sex: M+F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Efficacy of two vitamin E formulations in patients with abetalipoproteinemia and chylomicron retention disease.
2018-09
Oral Tocofersolan Corrects or Prevents Vitamin E Deficiency in Children With Chronic Cholestasis.
2016-12
Effect of hydrosoluble vitamin E on erythrocyte membrane lipid composition in patients with advanced cirrhosis: An open-label pilot trial.
2015-08
Guidelines for the diagnosis and management of chylomicron retention disease based on a review of the literature and the experience of two centers.
2010-09-29
Dosage and formulation issues: oral vitamin E therapy in children.
2010-02
Bioavailability of oral vitamin E formulations in adult volunteers and children with chronic cholestasis or cystic fibrosis.
2009-10
Determination of alpha-tocopherol in plasma by high performance liquid chromatography with fluorescence detection and stability of alpha-tocopherol under different conditions.
2004
Antioxidant capacity in Fasciola hepatica patients before and after treatment with triclabendazole alone or in combination with ascorbic acid (vitamin C) and tocofersolan (vitamin E).
2003
Final report on the safety assessment of Tocopherol, Tocopheryl Acetate, Tocopheryl Linoleate, Tocopheryl Linoleate/Oleate, Tocopheryl Nicotinate, Tocopheryl Succinate, Dioleyl Tocopheryl Methylsilanol, Potassium Ascorbyl Tocopheryl Phosphate, and Tocophersolan.
2002
Treatment of cholestatic children with water-soluble vitamin E (alpha-tocopheryl polyethylene glycol succinate): effects on serum vitamin E, lipid peroxides, and polyunsaturated fatty acids.
1997-02

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Tocophersolan (Vedrop) is given with or without water. This dose should be adjusted depending on the amount of vitamin E in the child’s blood. This should be checked regularly.
The recommended total daily dose in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis is 0.34 ml/kg/day (17 mg/kg of d-alpha-tocopherol in the form of tocofersolan). The dose should be prescribed in ml.
Route of Administration: Oral
In vitro studies using fibroblasts, enterocytes and Caco-2 cells conclude that Tocophersolan (tocofersolan) is taken up as the intact molecule and undergoes a slow hydrolysis reaction, intracellularly, to give PEG 1000 and Vitamin E (d-α tocopherol).
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:14:03 GMT 2025
Edited
by admin
on Mon Mar 31 18:14:03 GMT 2025
Record UNII
BVK87L5TNB
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
.ALPHA.-TOCOPHEROL CALCIUM SUCCINATE, D-
Common Name English
TOCOPHEROL CALCIUM SUCCINATE
WHO-DD  
Preferred Name English
J591.353E
Code English
Tocopherol calcium succinate [WHO-DD]
Common Name English
TOCOPHEROL CALCIUM SUCCINATE [JAN]
Common Name English
BUTANEDIOIC ACID, 1-((2R)-3,4-DIHYDRO-2,5,7,8-TETRAMETHYL-2-((4R,8R)-4,8,12-TRIMETHYLTRIDECYL)-2H-1-BENZOPYRAN-6-YL) ESTER, CALCIUM SALT (2:1)
Common Name English
D-.ALPHA.-TOCOPHEROL CALCIUM SUCCINATE
Common Name English
E-TAP S
Brand Name English
Code System Code Type Description
PUBCHEM
443968
Created by admin on Mon Mar 31 18:14:03 GMT 2025 , Edited by admin on Mon Mar 31 18:14:03 GMT 2025
PRIMARY
DAILYMED
BVK87L5TNB
Created by admin on Mon Mar 31 18:14:03 GMT 2025 , Edited by admin on Mon Mar 31 18:14:03 GMT 2025
PRIMARY
CAS
14464-85-8
Created by admin on Mon Mar 31 18:14:03 GMT 2025 , Edited by admin on Mon Mar 31 18:14:03 GMT 2025
PRIMARY
FDA UNII
BVK87L5TNB
Created by admin on Mon Mar 31 18:14:03 GMT 2025 , Edited by admin on Mon Mar 31 18:14:03 GMT 2025
PRIMARY
Related Record Type Details
ACTIVE MOIETY